Quantitative analysis of clonal bone marrow CD19+B cells: Use of B cell lineage trees to delineate their role in the pathogenesis of light chain amyloidosis

被引:12
作者
Manske, Michelle K.
Zuckerman, Neta S.
Timm, Michael M.
Maiden, Stephanie
Edelman, Hanna
Shahaf, Gitit
Barak, Michal
Dispenzieri, Angela
Gertz, Morie A.
Mehr, Ramit
Abraham, Roshini S.
机构
[1] Mayo Clin, Div Clin Biochem & Immunol, Cellular & Mol Immunol Lab, Coll Med, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Dept Internal Med, Div Hematol, Rochester, MN 55905 USA
[3] Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel
[4] Univ Madison, Dept Pharmacol, Madison, WI 53706 USA
基金
以色列科学基金会;
关键词
humans; B cells; immunoglobulin light chain amyloidosis; plasma cell dyscrasia; monoclonal gammopathy; clone;
D O I
10.1016/j.clim.2006.01.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Light chain amyloidosis (AL) is a bone marrow (BM) plasma cell neoplasia with systemic deposition of Ig light chain amyloid fibrils. Here, we report the identification of clonal CD19 B cells in the BM and the use of a novel mathematical algorithm to generate B cell lineage trees of the clonal CD19 B cells and CD138 plasma cells from the BM of AL patients to delineate the relationship between these two clonal populations. The CD19+ clonal B cells in the BM of AL patients related to the clonal plasma cells represent a pre-plasma cell precursor population. The B cell lineage trees from AL patients also show significant differences in clonal diversification and antigenic selection compared to clones from normal, healthy controls. These data provide a robust example of the use of graphical quantification methods in delineating the role of neoplastic precursors in the pathogenesis of hematopoietic malignancies. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:106 / 120
页数:15
相关论文
共 43 条
[1]   Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL) [J].
Abraham, RS ;
Geyer, SM ;
Price-Troska, TL ;
Allmer, C ;
Kyle, RA ;
Gertz, MA ;
Fonseca, R .
BLOOD, 2003, 101 (10) :3801-3808
[2]   MULTIPLE-MYELOMA - THE BIOLOGY OF MALIGNANT PLASMA-CELLS [J].
BARKER, HF ;
BALL, J ;
DREW, M ;
FRANKLIN, IM .
BLOOD REVIEWS, 1993, 7 (01) :19-23
[3]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[4]  
BERGSAGEL, 1995, BLOOD, V85, P3365
[5]   IN MULTIPLE-MYELOMA, CLONOTYPIC B-LYMPHOCYTES ARE DETECTABLE AMONG CD19(+) PERIPHERAL-BLOOD CELLS EXPRESSING CD38, CD56, AND MONOTYPIC IG LIGHT-CHAIN [J].
BERGSAGEL, PL ;
SMITH, AM ;
SZCZEPEK, A ;
MANT, MJ ;
BELCH, AR ;
PILARSKI, LM .
BLOOD, 1995, 85 (02) :436-447
[6]  
BERGSAGEL PL, 1994, CURR TOP MICROBIOL, V199, P17
[7]  
BILLADEAU D, 1992, BLOOD, V80, P1818
[8]  
Billadeau D, 1996, BLOOD, V88, P289
[9]   THE BONE-MARROW OF MULTIPLE-MYELOMA PATIENTS CONTAINS B-CELL POPULATIONS AT DIFFERENT STAGES OF DIFFERENTIATION THAT ARE CLONALLY RELATED TO THE MALIGNANT PLASMA-CELL [J].
BILLADEAU, D ;
AHMANN, G ;
GREIPP, P ;
VANNESS, B .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (03) :1023-1031
[10]   IDENTIFICATION OF MALIGNANT PLASMA-CELL PRECURSORS IN THE BONE-MARROW OF MULTIPLE-MYELOMA [J].
CALIGARISCAPPIO, F ;
BERGUI, L ;
TESIO, L ;
PIZZOLO, G ;
MALAVASI, F ;
CHILOSI, M ;
CAMPANA, D ;
VANCAMP, B ;
JANOSSY, G .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (03) :1243-1251